Background: About 20% of resectable oesophageal carcinoma is resistant to preoperative chemoradiotherapy. Here we hypothesised that the expression of the antiapoptotic gene Baculoviral inhibitor of apoptosis repeat containing (BIRC)3 induced by the transforming growth factor b activated kinase 1 (TAK1) might be responsible for the resistance to the proapoptotic effect of chemoradiotherapy in oesophageal carcinoma.
did not benefit from chemoradiotherapy but were exposed to its negative consequences such as toxicity and delayed surgical therapy. These clinical evidences provide a strong argument for the urgent development of molecular biomarkers able to predict primary resistance to preoperative chemoradiotherapy in oesophageal and oesophagogastric junction adenocarcinoma, in order to avoid this preoperative treatment in those patients unlikely to benefit. Baculoviral inhibitor of apoptosis (IAP) repeat containing (BIRC)3 gene encodes for the cellular IAP 2 protein (Srinivasula and Ashwell, 2008) , a member of the IAP family that inhibits apoptosis by directly inhibiting caspases cascade (Wang et al, 1998; Park et al, 2004) . A sequence analysis of the BIRC3 promoter revealed two critical nuclear factor kB (NF-kB) and two potential activator protein-1 (AP-1)-binding sites (Hong et al, 2000) . Transforming growth factor (TGF)-b activated kinase 1 (TAK1, also called MAP3K7) is a serine/threonine kinase with a critical role in the inflammatory responses and cell survival control by integrating signals from various cytokines-including interleukin-1, TGF-b, and TNFa-and controlling, in turn, the activation of different transcription factors, including AP-1 and NF-kB (Sakurai, 2012) . We recently demonstrated that suppressing the expression of BIRC3 through the genetic silencing or the pharmacological inhibition of TAK1 markedly reverted the intrinsic chemoresistance of pancreatic cancer .
In this present study, we hypothesised that the TAK1-regulated expression of BIRC3 might be responsible for the resistance of distal oesophageal and oesophagogastric junction carcinoma to the proapoptotic effect of chemoradiotherapeutic treatments. Thus, the expression of BIRC3 gene might serve as a putative biomarker for the selection of patients with oesophageal and oesophagogastric junction adenocarcinoma eligible for preoperative chemoradiotherapy.
MATERIALS AND METHODS
Cell lines and reagents. The human distal oesophageal adenocarcinoma cell lines, FLO-1 and KYAE-1, were purchased from European Collection of Cell Cultures (Salisbury, UK). The human pancreatic cancer cell line AsPc-1 was purchased from the American Type Culture Collection (Manassas, VA, USA). AsPC-1 shTAK1 cells stably expressing small hairpin RNA sequences to knockdown the expression of TAK1 has been previously described in Melisi et al (2011) . Distal oesophageal adenocarcinoma and pancreatic cancer cell lines were maintained in RPMI 1640 and Dulbecco's modified Eagle's media (LONZA, Basel, Switzerland), respectively, supplemented with 10% heat-inactivated FBS, 20 mmol l À 1 HEPES (pH 7.4), penicillin (100 UI ml À 1 ), streptomycin (100 mg ml À 1 ), and 4 mmol l À 1 glutamine (ICN Biomedicals Ltd., Irvine, CA, USA) in a humidified atmosphere of 95% air and 5% CO 2 at 37 1C. The TAK1 kinase activity was targeted using (5Z)-7-oxozeaenol TAK1 kinase selective inhibitor (TOCRIS bioscience, Bristol, UK). For in vitro assays, (5Z)-7-oxozeaenol was dissolved in 100% dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM. Cell irradiation was performed using a GammaCell 40 irradiator (Best Theratronics Ltd., Ottawa, Canada) as previously described in Melisi et al, 2009 .
Protein extraction and western blotting. Western blot analyses were performed as previously described in Raben et al (2004) . In brief, cell lines were washed twice with cold phosphate-buffered saline and lysed at 4 1C into radioimmunoprecipitation assay buffer (50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) plus protease inhibitor mix (50 nM sodium pyrophosphate, 0,5 mM sodium orthovanadate, 50 mM NaF, 5 mg ml À 1 aprotinin, 0.5 mM PMSF (fenilmetilsulfonil hydrofluoride), 1 mM DTT, 2 mg ml À 1 leupeptin, 5 mg ml À 1 benzamidine, 1 mg ml À 1 pepstatine). Lysates were clarified by centrifugation and protein concentrations were determined by BCA assay (Thermo Scientific, Waltham, MA, USA). Each lysate was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed (1 : 1000) with rabbit monoclonal antibodies against BIRC3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and cleaved caspase 3 (Cell Signalling Technology, Danvers, MA, USA), or goat polyclonal antibodies against g-tubulin (Santa Cruz Biotechnology, CA, USA). Immunoreactive proteins were detected using an enhanced chemiluminescence reagent (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Images were captured either on film or by LAS4000 Digital Image Scanning System (GE Healthcare, Little Chalfont, UK).
Patients and treatment. Patients considered for analyses were affected by cT2-4, Nx, M0 adenocarcinoma, or squamous cell carcinoma of the distal oesophagus or the oesophagogastric junction (siewert type I and II), and enrolled in a recent study of preoperative therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy as reported in Pasini et al (2013) and Zanoni et al (2013 (Verlato et al, 2010 ; SPR1-2 ¼ responders vs SPR3-4 ¼ non responders).
A fresh specimen from the tumour was collected endoscopically at diagnosis and placed immediately into RNALater (Life Technologies, Carlsbad, CA, USA), washed in ice-cold RNAasefree water for 5 min and 'snap' frozen in liquid nitrogen and stored at À 80 1C for 24 h.
RNA was isolated by Trizol reagent as indicated by the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The reverse transcription-PCR assay was performed as previously described in Rosa et al (2011) accordingly with the high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). The mRNA expression of BIRC3 was quantified using a SYBR green-based real-time PCR analysis and the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). Gene expression was tested in each sample in four replicates. To quantify the relative changes in gene expression, the 2 À DDCT method was used and reactions were normalised to endogenous control gene b-actin expression levels. The BIRC3 median expression in normal oesophagogastric mucosa samples from six different healthy subjects was used as calibrator (Livak and Schmittgen, 2001 ).
Statistical analysis. All results were expressed as the mean and 95% confidence interval for at least three independent experiments performed in triplicate. Drug interactions were studied for synergistic effect according to Chou and Talalay method by CalcuSyn software (Chou and Talalay, 1984) . Receiver operator characteristic (ROC) analyses were performed to determine the performance of BIRC3 expression levels in distinguishing patients with sensitive or resistant carcinoma. The optimal cutoff thresholds for BIRC3 gene expression were obtained based on the maximisation of the Youden's statistics J ¼ sensitivity þ specificity þ 1 (Youden, 1950) using an R-based software as described in Budczies et al (2012) . Statistical analyses were performed using SPSS Statistics 22 (IBM Corporation, Somers, NY, USA), GraphPad Prism software program (version 6.0; GraphPad Software, San Diego, CA), and the statistical language R.
RESULTS
BIRC3 expression is elevated in distal oesophageal adenocarcinoma cell lines, and regulated by TAK1 kinase activity. In order to demonstrate our hypothesis, we used the two certified distal oesophageal adenocarcinoma FLO-1 and KYAE-1 cell lines (Boonstra et al, 2010) , and we initially determined the basal expression of BIRC3 compared with the TAK1-positive pancreatic cancer cell line AsPC-1, as positive control, or the same cells stably silenced for TAK1 expression ( Figure 1A ). To verify that the inhibition of TAK1 could modulate the expression of BIRC3 in oesophageal adenocarcinoma, we used the selective TAK1 inhibitor (5Z)-7-oxozeaenol, and we demonstrated that the inhibition of TAK1 markedly suppressed the expression of BIRC3 within 24 h of treatment in both FLO-1 and KYAE-1 distal oesophageal adenocarcinoma cell lines ( Figure 1B and C). Dowregulating BIRC3 expression through the inhibition of TAK1 sensitises oesophageal adenocarcinoma cell lines to the proapoptotic activity of classic chemotherapeutic agents. To test our hypothesis that TAK1-regulated expression of BIRC3 would be responsible for the chemoresistance of distal oesophageal adenocarcinoma, we initially determined the sensitivity of FLO-1 and KYAE-1 cell lines to three chemotherapeutic agents that are currently used for the preoperative treatment of this disease: the nucleoside analogue 5-fluorouracile, the DNA-intercalating agent cisplatin, and the microtubule stabiliser paclitaxel (Supplementary Figure S1 ). Whereas FLO-1 and KYAE-1 cell lines were protected towards the proapoptotic activity of these chemotherapeutic agents as single-agent treatment or in their triple combination, the inhibition of the expression of BIRC3 by introducing the TAK1 inhibitor (5Z)-7-oxozeaenol was able to modulate their chemoresistance, as demonstrated by significantly higher levels of PARP1 and caspase3 cleavage (Figure 2A and B), as well as Annexin-Vpositive cells ( Figure 2C) .
Thus, we combined equitoxic doses of the three chemotherapeutic agents and we measured a statistically significant potentiation of their in vitro antitumour activity when co-administered with increasing doses of TAK1 inhibitor (5Z)-7-oxozeaenol ( Figure 2D and E). Moreover, drug interactions were studied for synergistic effect according to Chou and Talalay method (Chou and Talalay, 1984) . FLO-1 and KYAE-1 cell lines were treated with increasing doses of 5-fuorouracil, cisplatin, or paclitaxel administered as single agent or in their double or triple combination with or without pretreatment with (5Z)-7-oxozeaenol. The pharmacological inhibition of TAK1 induced a strong synergistic antiproliferative effect in all tested combinations and this effect is even more evident when we treated cells with the triple polychemotherapy approach as demonstrated by combination indexes lower than one (Figure 2F and G; Supplementary Table S1 ).
These data suggest that the TAK1-regulated expression of BIRC3 is an important mediator of resistance to chemotherapeutic agents in oesophageal adenocarcinoma in vitro models. Downregulating BIRC3 expression through the inhibition of TAK1 sensitises oesophageal adenocarcinoma cell lines to radiotherapy. To test our hypothesis that TAK1-regulated expression of BIRC3 would be responsible for the resistance of distal oesophageal adenocarcinoma to radiotherapy, we treated FLO-1 and KYAE-1 cell lines with low doses of (5Z)-7-oxozeaenol or DMSO as control plus increasing doses of radiotherapy. The pharmacological inhibition of TAK1 induced a significant downregulation of BIRC3, relieving a crucial cell escape mechanism and thus improving activation of the apoptotic cascade as demonstrated by an increased level of caspase3 and PARP1 cleavage products and AnnexinV staining in both FLO-1 and KYAE-1 cell lines ( Figure 3A , B and C).
These data suggest that the TAK1-regulated expression of BIRC3 could be an important mediator of resistance to radiotherapy in oesophageal adenocarcinoma in vitro models.
Correlation between BIRC3 expression and the response to preoperative chemoradiotherapy treatment in oesophageal and oesophagogastric junction adenocarcinoma and squamous cell carcinoma patients. In order to translate our findings into the clinic setting and evaluate the potential of BIRC3 expression to predict chemoradioresistance in oesophageal and oesophagogastric junction cancers, we measured the expression levels of BIRC3 mRNA in pretreatment biopsies from 32 patients with adenocarcinoma and 33 patients with squamous cell carcinoma treated with a preoperative schedule including weekly docetaxel and cisplatin, continuous infusion of 5-fluorouracil and concomitant radiotherapy as described in Pasini et al (2013) . Patient characteristics are shown in Table 1 . The majority of patients were men (86%). Adenocarcinoma and squamous cell carcinoma histological subtypes were equally represented. Most of the patients had T3 or higher tumours, and half of them had node positive disease. Initially, we demonstrated a significantly lower expression of BIRC3 in the more sensitive population of patients affect by squamous cell carcinoma than in those affected by adenocarcinoma ( Figure 4A ). Next, we performed ROC analyses to validate the potential usefulness of BIRC3 tumour expression as a biomarker to predict response to preoperative chemoradiotherapy. Whereas tumour expression levels of BIRC3 could not distinguish between sensitive or resistant oesophageal squamous cell carcinoma, it significantly discriminated patients with sensitive or resistant adenocarcinoma, with AUC values of 0.7773 or 0.8074 using the SPR or TRG classifications, respectively ( Figure 4B) . A 2 À DDCT of 2.373 or 4.395 were identified as the optimal cutoff thresholds considering SPR or TRG classifications, respectively. These cutoff thresholds had a sensitivity of 62.5% (95% CI ¼ 81.5-38.6%) and specificity of 93.8% (95% CI ¼ 99.7-71.7%) by considering the SPR classification, or a sensitivity of 63% (95% CI ¼ 78.5-44.2%) and specificity of 100% (95% CI ¼ 100-56.6%) by considering the TRG classification for response prediction ( Figure 4C ). In particular, pathologic complete response was achieved in 6 out of 11 (54.5%) of patients with BIRC3 expression lower than cutoff, and only in 4 out of 21 (19.0%) of patients with BIRC3 expression higher than cutoff by considering the SPR classification, and in 9 out of 17 (52.9%) of patients with BIRC3 expression lower than cutoff, and in 6 out of 15 (40%) of patients with BIRC3 expression higher than cutoff by considering the TRG classification for response prediction ( Figure 4D ).
DISCUSSION
In this study, we demonstrated that the suppression of the expression of the antiapoptotic gene BIRC3 regulated by TAK1 significantly increases the sensitivity of oesophageal adenocarcinoma cells to the chemotherapy and radiotherapy-induced cell death. More importantly, we demonstrated that BIRC3 gene expression is a potential biomarker for identifying patients with adenocarcinoma of the distal oesophagus and of the oesophagogastric junction that could most likely benefit from preoperative chemoradiotherapy.
The incidence of the oesophageal adenocarcinoma is rapidly and constantly rising, and the clinical outcomes with current therapeutic approaches remain extremely poor. Thus, there is an increasingly urgent clinical need for developing novel therapeutic strategies able to overcome tumour resistance, as well as for optimising the currently available therapeutic modalities through a more accurate selection of patients in order to avoid the use of ineffective and potentially toxic treatments.
The main obstacle to the clinical efficacy of chemo-and radiotherapy is the pre-existence of or the development of cellular drug resistance (Melisi et al, 2013) , a feature that appears to be closely connected to alterations in key pathways involved in cell cycle checkpoint control and, most importantly, apoptosis (DeVita and Chu, 2008) . A number of recent studies have demonstrated the potential of different molecular markers to predict histopathological response in patients with oesophageal adenocarcinoma receiving preoperative treatments, mostly including growth factor receptors, tumour suppressor genes, and genes associated with chemotherapeutic agents metabolism (reviewed in Bain and Petty (2010) ). The TAK1 is a unique member of the MAP3K family (Mihaly et al, 2014) , representing the active component of a larger protein signalling complex including TAK1-binding proteins and TRAF6, that integrates several signal transduction cascades, and sustains, in turn, the activation of the most potent antiapoptotic transcriptional factor NF-kB (Melisi and Chiao, 2007; Carbone and Melisi, 2012) . We recently demonstrated TAK1 as one of the major determinant of the unique resistance of pancreatic cancer to the proapoptotic activity of classic chemotherapeutic agents through the transcription of the antiapoptotic gene BIRC3 . In this present study, we corroborate these evidences by demonstrating that this role in treatment resistance for the axis TAK1-BIRC3 could also be translated in models of oesophageal adenocarcinoma. Most importantly, our study is the first to demonstrate a significant role for the antiapoptotic gene BIRC3 in predicting histopathological response to preoperative treatments in patients with solid tumours, and, in particular, with oesophageal adenocarcinoma.
The relevance of chemoresistance in oesophageal and oesophagogastric junction adenocarcinoma has been established in a recent analysis involving 400 patients with resectable disease who received preoperative chemotherapy. This study demonstrated that local downstaging after preoperative chemotherapy was the strongest independent predictor of survival in this clinical setting. Tumour stage after preoperative chemotherapy was more relevant for prognosis than initial stage at diagnosis (Davies et al, 2014) . In our present study, we analysed the association of BIRC3 expression with patients' survival by considering the established cutoff value of 2.373. Although not statistically significant (P ¼ 0.262), we measured a median overall survival (mOS) of 30 vs 64 months for patients with tumour expressing higher or lower levels of BIRC3, respectively (data not shown). Collectively, these evidences corroborate the importance of an early identification of patients who could not benefit from preoperative treatment, and, in turn, the relevance of BIRC3 expression in predicting local downstaging from preoperative treatment in oesophageal and oesophagogastric junction adenocarcinoma.
The most recent and solid evidences in supporting for a preoperative combined chemoradiotherapy followed by surgery approach have been provided by the results of the Chemotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) (van Hagen et al, 2012 ). An important question raised by the CROSS trial is the different relevance for preoperative chemoradiotherapy between the two different histological subtypes. For the intention-to-treat population in this study, preoperative chemoradiotherapy provided a 23% increase in radical resection rate (92% vs 69%, Po0.001), and doubled the mOS duration (49.4 vs 24.0 months, Po0.003) when compared with surgery. However, in the post hoc analysis, according to histological subtypes, the mOS advantage provided by preoperative chemoradiotherapy was highly significant only for the squamous cell subtype (HR of 0.422 (95% CI 0.226-0.788)), while among adenocarcinomas the survival gain obtained by the addition of preoperative treatments did not achieve statistical significance (HR of 0.741 (95% CI 0.536-1.024)), suggesting that the difference between the study arms was driven by the squamous cell subtype despite this being the less numerous group. A pathological complete response to preoperative chemoradiotherapy was obtained in 23% of adenocarcinomas vs 49% of squamous cell carcinoma (P ¼ 0.008; van Hagen et al, 2012) . These analyses support a divergent intrinsic biological behaviour, and corroborate the evidences for a different mutational prolife between adenocarcinoma and squamous cell histological subtypes (Agrawal et al, 2012; Dulak et al, 2013; Song et al, 2014) . In this regard, we demonstrated a significantly lower expression of BIRC3 in squamous cell carcinomas than in adenocarcinomas, supporting the hypothesis that the expression of this antiapoptotic gene could be a mechanism to explain the different resistance to chemoradiotherapy between the two histological subtypes.
However, this study had some limitations, including its retrospective nature, the limited number of patients analysed, and the lack of an external validation analysis on an independent validation cohort.
In conclusion, this study demonstrates that the reduction of the expression on the antiapoptotic gene BIRC3 through the inhibition of the kinase activity of TAK1 is a valid approach for reverting the resistance of oesophageal adenocarcinoma to chemoradiotherapy. The inhibition of TAK1 deserves further development for the treatment of oesophageal adenocarcinoma. Most importantly, this study candidates BIRC3 as one of the potentially useful predictive marker for discriminating patients with oesophageal and oesophagogastric junction adenocarcinoma who will most likely benefit from preoperative chemoradiotherapy. Further investigations with larger prospective studies in this clinical setting are warranted. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.
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